Why BEAM-302’s latest data matters for Beam Therapeutics stock

Beam Therapeutics (BEAM) has drawn fresh attention after presenting updated Phase 1/2 BEAM-302 data for alpha-1 antitrypsin deficiency at the ATS 2026 conference, highlighting safety outcomes, durability signals and reduced neutrophil elastase activity.

The updated BEAM-302 data has arrived alongside strong momentum in the stock, with a 7 day share price return of 14.98% and a year to date share price return of 21.33%. The 1 year total shareholder return of 108.02% contrasts with a 5 year total shareholder return that is down 60.14%, suggesting sentiment has shifted sharply in the short term.

If this kind of gene editing progress has your attention, it can be worth scanning other healthcare and biotech opportunities using a focused screener for 37 healthcare AI stocks

With the stock up sharply in the short term but still carrying a 5-year total shareholder return that is down 60.14%, and trading below the average analyst price target, is there still a fresh opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 78% Undervalued

Against a last close of $32.93, the most followed narrative on Beam Therapeutics pins fair value at $150, setting a very different reference point for BEAM-302’s latest readout.

This sum-of-the-parts rNPV analysis of only the two lead assets (BEAM-101 and BEAM-302) derives a base-case intrinsic value of $65 per share.

Crucially, this $65 base-case valuation does not assign any value to the emerging BEAM-301 (GSDIa) or BEAM-201 (T-ALL) programs, nor does it include the transformative, multi-billion dollar option value of the ESCAPE platform, suggesting significant, unpriced upside remains.

Want to understand why a fair value almost five times the current share price still only partially credits the pipeline? The rNPV hinges on concentrated assumptions around two programs, selective revenue build up, margin progression and a specific discount rate that leaves several assets effectively priced at zero in the model.

Result: Fair Value of $150 (UNDERVALUED)

However, this bullish narrative still faces real pressure points, including any weaker than expected BEAM-302 follow up data and potential delays or setbacks across the wider pipeline.

Another View: What The Market Multiple Is Signalling

That $150 fair value from the rNPV model sits against a very different message from the current sales multiple. Beam trades on a P/S of 20x, compared with 10.7x for the US biotech industry, 8.7x for peers and a fair ratio of just 0.7x. For you, that raises a clear question: is the market overpaying for promise, or is the rNPV underweighting risk?

Next Steps

With mixed signals on valuation and sentiment running high, this is the moment to look under the hood yourself and decide how you feel about the risk reward trade off. To see both sides clearly, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If BEAM has sharpened your focus, do not stop here. The next move could come from stocks that are not yet on your radar.

• Target resilient income by reviewing companies that appear built to keep paying, starting with 10 dividend fortresses.
• Hunt for potential mispricings by scanning companies that combine quality with appealing valuations through 46 high quality undervalued stocks.
• Spot quieter opportunities with strong fundamentals before they get crowded by checking the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.